SCHEMBL6337356

SCHEMBL6337356

CCCCOc1ccc2c(c1)C(=O)CCCO2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.48
ACHE P22303 1/20 0.44
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 3/20 0.43
KDM4E B2RXH2 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
BRD4 O60885 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6348515 0.95 MAOB (0.46) MAOBACHEALDH1A1MEN1KMT2A
SCHEMBL2976534 0.86 MAOB (0.54) MAOBALDH1A1MEN1KMT2ANPC1
SCHEMBL29814619 0.81 NPC1 (0.52) MAOBALDH1A1NPC1RAB9AGAA
SCHEMBL8029261 0.81 NPC1 (0.52) MAOBALDH1A1NPC1RAB9AGAA
SCHEMBL13264507 0.81 MAOB (0.70) MAOBACHEALDH1A1NPC1RAB9A
SCHEMBL6836610 0.80 MAOB (0.53) MAOBALDH1A1MEN1KMT2ANPC1
SCHEMBL25889778 0.80 HTR1A (0.55) MAOBALDH1A1NPC1RAB9AHPGD
SCHEMBL28031565 0.79 MAOB (0.52) MAOBACHEALDH1A1NPC1RAB9A
SCHEMBL8034908 0.79 MAOB (0.69) MAOBALDH1A1MEN1KMT2ANPC1
SCHEMBL28030975 0.78 MAOB (0.51) MAOBACHEALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6908947-B2 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-21 US disclosed
EP-0861836-B1 Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity AVENTIS PHARMA GMBH (DE) 2004-12-29 EP disclosed
US-20020072514-A1 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them HOECHST AKTIENGESELLSCHAFT 2002-06-13 US disclosed
US-6333349-B1 POTASSIUM CHANNEL OR THE I.SUB.KS CHANNEL OPENED BY CYCLIC ADENOSINE MONOPHOSPHATE AS POTASSIUM CHANNEL ACTIVATORS AND CARDIOVASCULAR DISORDERS, ANTIARRHYTHMIAS, FOR THE TREATMENT OF ULCERS OF THE GASTROINTESTINAL REGION OR FOR THE TREATMENT AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-12-25 US disclosed
EP-0861836-A1 Sulfonamido substituted condensed, seven-membered ring compounds with potassium channel blocking activity HOECHST AKTIENGESELLSCHAFT (DE) 1998-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072514-A1 Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them KCNN3, KCNJ1, KCNJ11 MAOB 3247/4885ACHE 2594/4885ALDH1A1 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.